Vaximm
Clinical-stage biotechnology company developing an oral T‑cell immunotherapy platform that uses a genetically modified eukaryotic oral delivery vector to target gut-associated lymphoid tissue and elicit systemic cytotoxic T‑cell responses for oncology indications. The organization has advanced candidates through Phase I/II clinical studies, has published clinical data, and pursues partnerships and licensing to support development and commercialization.
Industries
Nr. of Employees
small (1-50)
Vaximm
Products
VXM01
An oral T‑cell immunotherapy candidate that delivers genetic sequences to induce T‑cell responses against VEGFR2, evaluated in Phase I/II oncology trials including glioblastoma and pancreatic cancer.
VXM01
An oral T‑cell immunotherapy candidate that delivers genetic sequences to induce T‑cell responses against VEGFR2, evaluated in Phase I/II oncology trials including glioblastoma and pancreatic cancer.
Services
Clinical development collaborations
Collaborative design and execution of early‑phase oncology trials, including combination regimens with checkpoint inhibitors and external pharma partners.
Platform licensing and regional development partnerships
Out‑licensing and strategic licensing arrangements to third parties for development and commercialization in defined territories.
Clinical development collaborations
Collaborative design and execution of early‑phase oncology trials, including combination regimens with checkpoint inhibitors and external pharma partners.
Platform licensing and regional development partnerships
Out‑licensing and strategic licensing arrangements to third parties for development and commercialization in defined territories.
Expertise Areas
- Oral immunotherapy development
- T‑cell focused oncology immunotherapy
- Early‑stage clinical trial management (Phase I/II)
- Preclinical immunology and vaccine development
Key Technologies
- Genetically modified eukaryotic oral delivery vectors
- GALT / Peyer’s patch targeting
- Antigen‑specific CD8+ and CD4+ T‑cell activation
- Platform modular 'plug-and-play' antigen design